Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Earnings: Report Dates and Results
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.24, above the $0.23 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AMRX has an expected report date of Feb 25, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 14.3% above the $0.21 reported for the quarter ended Dec 31, 2025.
AMRX Earnings Call
The latest AMRX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, AMRX beat 29, missed 8 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $862.68M, up 10.0% from $784.51M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.24 | $0.23 | $0.20 - $0.28 | +4.35% | Beat | +41.2% | 7 | 0 up, 1 down | Nov 3, 2026 | $862.68M |
| Jun 30, 2026 | $0.27 | $0.24 | $0.20 - $0.26 | +12.50% | Beat | +8.0% | 5 | 2 up, 1 down | Jul 30, 2026 | $796.20M |
| Mar 31, 2026 | $0.27 | $0.19 | $0.15 - $0.19 | +38.96% | Beat | +28.6% | 5 | 1 up, 0 down | May 7, 2026 | $722.52M |
| Dec 31, 2025 | $0.21 | $0.18 | $0.16 - $0.20 | +16.67% | Beat | +75.0% | 5 | 1 up, 0 down | Feb 27, 2026 | $814.32M |
| Sep 30, 2025 | $0.17 | $0.14 | $0.09 - $0.17 | +21.43% | Beat | +6.3% | 4 | 1 up, 2 down | Oct 30, 2025 | $784.51M |
| Jun 30, 2025 | $0.25 | $0.17 | $0.16 - $0.20 | +47.06% | Beat | +56.3% | 4 | 1 up, 0 down | Aug 5, 2025 | $724.51M |
| Mar 31, 2025 | $0.21 | $0.15 | $0.13 - $0.16 | +40.00% | Beat | +50.0% | 3 | 0 up, 1 down | May 2, 2025 | $695.42M |
| Dec 31, 2024 | $0.12 | $0.15 | $0.15 - $0.16 | -20.00% | Miss | -14.3% | 4 | 1 up, 1 down | Feb 28, 2025 | $730.52M |
| Sep 30, 2024 | $0.16 | $0.14 | $0.12 - $0.15 | +14.29% | Beat | -15.8% | 4 | 1 up, 0 down | Nov 8, 2024 | $702.47M |
| Jun 30, 2024 | $0.16 | $0.14 | $0.12 - $0.17 | +14.29% | Beat | -15.8% | 4 | 1 up, 0 down | Aug 9, 2024 | $701.78M |
| Mar 31, 2024 | $0.14 | $0.09 | $0.08 - $0.11 | +55.56% | Beat | +16.7% | 5 | 0 up, 0 down | May 3, 2024 | $659.19M |
| Dec 31, 2023 | $0.14 | $0.09 | $0.07 - $0.15 | +55.56% | Beat | -39.1% | 5 | 0 up, 0 down | Mar 1, 2024 | $616.98M |
| Sep 30, 2023 | $0.19 | $0.13 | $0.09 - $0.14 | +46.15% | Beat | +35.7% | 5 | 1 up, 0 down | Nov 7, 2023 | $620.04M |
| Jun 30, 2023 | $0.19 | $0.10 | $0.07 - $0.14 | +90.00% | Beat | 0.0% | 5 | 0 up, 0 down | Aug 4, 2023 | $599.05M |
| Mar 31, 2023 | $0.12 | $0.10 | $0.09 - $0.10 | +20.00% | Beat | 0.0% | 5 | 2 up, 0 down | May 5, 2023 | $557.54M |
| Dec 31, 2022 | $0.23 | $0.21 | $0.19 - $0.22 | +9.52% | Beat | +27.8% | 7 | 0 up, 0 down | Mar 2, 2023 | $609.76M |
| Sep 30, 2022 | $0.14 | $0.18 | $0.14 - $0.20 | -22.22% | Miss | -33.3% | 7 | 0 up, 1 down | Nov 4, 2022 | $545.56M |
| Jun 30, 2022 | $0.19 | $0.19 | $0.18 - $0.21 | 0.00% | In line | -24.0% | 7 | 0 up, 1 down | Aug 5, 2022 | $559.36M |
| Mar 31, 2022 | $0.12 | $0.13 | $0.11 - $0.14 | -7.69% | Miss | -40.0% | 7 | 0 up, 1 down | May 4, 2022 | $497.63M |
| Dec 31, 2021 | $0.18 | $0.20 | $0.17 - $0.22 | -10.00% | Miss | +28.6% | 7 | 0 up, 0 down | Mar 2, 2022 | $536.90M |
| Sep 30, 2021 | $0.21 | $0.20 | $0.18 - $0.24 | +5.00% | Beat | +31.2% | 7 | N/A | Nov 3, 2021 | $528.59M |
| Jun 30, 2021 | $0.25 | $0.18 | $0.17 - $0.20 | +38.89% | Beat | +92.3% | 8 | N/A | Aug 9, 2021 | $535.08M |
| Mar 31, 2021 | $0.20 | $0.18 | $0.15 - $0.20 | +11.11% | Beat | 0.0% | 11 | N/A | May 7, 2021 | $493.11M |
| Dec 31, 2020 | $0.14 | $0.13 | $0.10 - $0.16 | +7.69% | Beat | +75.0% | 11 | N/A | Feb 26, 2021 | $510.03M |
| Sep 30, 2020 | $0.16 | $0.12 | $0.10 - $0.13 | +33.33% | Beat | +300.0% | 11 | N/A | Nov 6, 2020 | $519.29M |
| Jun 30, 2020 | $0.13 | $0.10 | $0.06 - $0.11 | +30.00% | Beat | +44.4% | 12 | N/A | Aug 6, 2020 | $464.66M |
| Mar 31, 2020 | $0.20 | $0.09 | $0.05 - $0.14 | +122.22% | Beat | +42.9% | 11 | N/A | May 11, 2020 | $498.53M |
| Dec 31, 2019 | $0.08 | $0.05 | $0.02 - $0.09 | +60.00% | Beat | -75.8% | 11 | N/A | Feb 26, 2020 | $397.33M |
| Sep 30, 2019 | $0.04 | $0.13 | $0.10 - $0.28 | -69.23% | Miss | -85.7% | 13 | N/A | Nov 6, 2019 | $378.28M |
| Jun 30, 2019 | $0.09 | $0.12 | $0.05 - $0.27 | -25.00% | Miss | -62.5% | 12 | N/A | Aug 5, 2019 | $404.64M |
| Mar 31, 2019 | $0.14 | $0.18 | $0.12 - $0.21 | -22.22% | Miss | 0.0% | 11 | N/A | May 9, 2019 | $446.12M |
| Dec 31, 2018 | $0.33 | $0.27 | $0.24 - $0.34 | +22.22% | Beat | +200.0% | 11 | N/A | Feb 28, 2019 | $497.53M |
| Sep 30, 2018 | $0.28 | $0.27 | $0.26 - $0.29 | +3.70% | Beat | +21.7% | 13 | N/A | Nov 7, 2018 | $476.49M |
| Jun 30, 2018 | $0.24 | $0.22 | $0.17 - $0.27 | +9.09% | Beat | +33.3% | 15 | N/A | Aug 9, 2018 | $413.79M |
| Mar 31, 2018 | $0.14 | $0.10 | N/A | +40.00% | Beat | +27.3% | N/A | N/A | May 7, 2018 | $275.19M |
| Dec 31, 2017 | $0.11 | $0.11 | N/A | 0.00% | In line | -31.3% | N/A | N/A | Mar 1, 2018 | $293.37M |
| Sep 30, 2017 | $0.23 | $0.20 | N/A | +15.00% | Beat | -37.8% | N/A | N/A | Nov 9, 2017 | $254.73M |
| Jun 30, 2017 | $0.18 | $0.14 | N/A | +28.57% | Beat | -14.3% | N/A | N/A | Aug 9, 2017 | $259.87M |
| Mar 31, 2017 | $0.11 | $0.13 | N/A | -15.38% | Miss | -74.4% | N/A | N/A | May 10, 2017 | $225.68M |
| Dec 31, 2016 | $0.16 | $0.16 | N/A | 0.00% | In line | -74.2% | N/A | N/A | Mar 1, 2017 | $298.58M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.84, up 44.8% from the year before. It was $1.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.84 | +44.8% |
| Dec 31, 2024 | $0.58 | -9.4% |
| Dec 31, 2023 | $0.64 | N/A |
| Dec 31, 2022 | $0.68 | -19.0% |
| Dec 31, 2021 | $0.84 | +33.3% |
| Dec 31, 2020 | $0.63 | +80.0% |
| Dec 31, 2019 | $0.35 | -64.6% |
| Dec 31, 2018 | $0.99 | +57.1% |
| Dec 31, 2017 | $0.63 | -46.2% |
| Dec 31, 2016 | $1.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,351 | 12 | |
| 2026Q2 | Jun 30, 2026 | 4,825 | 10 | |
| 2026Q1 | Mar 31, 2026 | 5,899 | 11 | |
| 2025Q4 | Dec 31, 2025 | 5,547 | 10 | |
| 2025Q3 | Sep 30, 2025 | 4,648 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,349 | 10 | |
| 2025Q1 | Mar 31, 2025 | 4,552 | 8 | |
| 2024Q4 | Dec 31, 2024 | 5,776 | 11 |
2026Q3 Earnings Call
Opening remarks
Tony DiMeo Head of Investor Relations Good morning, and thank you for joining Amneal Pharmaceuticals Third Quarter 2026 Earnings Call. Today, we issued a press release reporting Q3 results. The earnings press release and presentation are available on the IR page of amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the sections entitled "Cautionary Statements on Forward-Looking Statements" in our press release and presentation for factors that may impact future performance. We also discuss non-GAAP measures. Information on the use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Chirag and Chintu Patel, co-founders and co-CEOs, Tasos Konidaris, CFO, Joe Renda for specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag.
Chirag Patel Co-CEO Thank you, Tony. Good morning, everyone. Today, Amneal is a stronger, more diversified company than ever before, with a portfolio focused on high-value products designed to drive durable growth. We've expanded across specialty, biosimilars, and complex products while building the capabilities and capacity to drive these businesses long term. 2026 marks our seventh consecutive year of top- and bottom-line growth, a track record that stands out in the industry. Our third-quarter performance reflects that progress, with revenue of $863 million, up 10%, adjusted EBITDA of $207 million, up 30%, and adjusted EPS of $0.26, up 53%. The breadth of our portfolio and the depth of our pipeline give us confidence that we are still early in realizing Amneal's full potential. Let me highlight the progress across our key growth areas. First, in biosimilars, we closed the Kashiv transaction in Q3. Amneal now has the end-to-end capabilities to succeed in biosimilars, with R&D, manufacturing, and commercial capabilities in-house. Now it is all about execution. From a macro perspective, we have access to a large and growing biosimilar market, with approximately $234 billion of U.S. biologic sales losing exclusivity over the next decade. At the same time, streamlined regulatory pathways, new commercial models such as private labels, and accelerating market adoption are creating a major inflection point for the U.S. biosimilar industry. Against this backdrop, our portfolio strategy is deliberately differentiated, balancing targeted lower-competition molecules with a select number of broader biologic opportunities. We believe this approach positions Amneal to capture attractive economics and sustain long-term value creation. For Amneal, biosimilars are a natural extension of our purpose: making key medicines more accessible and affordable while building a durable growth platform. Biologics account for more than half of U.S.
Frequently Asked Questions About AMRX
When is Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings date?
Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings report is expected for Feb 25, 2027.
Did AMRX beat earnings estimates last quarter?
Yes. Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.24 for the quarter ended Sep 30, 2026, above the $0.23 estimate, a 4.35% surprise.
What EPS do analysts expect from AMRX next quarter?
The consensus EPS estimate for Amneal Pharmaceuticals, Inc. Class A Common Stock for the quarter ending Dec 31, 2026 is $0.24 from 9 analysts, with estimates from $0.22 to $0.26.
How often does AMRX beat earnings estimates?
Amneal Pharmaceuticals, Inc. Class A Common Stock beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +20.12%.
AMRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors